Overview

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

Status:
Completed
Trial end date:
2021-07-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company